Gaze Stabilization vs Oculomotor Exercises on Cybersickness in Computer Users (GAZE-CS)

May 23, 2026 updated by: Dr. Marium Zafar, University of Faisalabad

Effectiveness of Gaze Stabilization Exercises Versus Oculomotor Exercises on Cybersickness in Computer Users: A Randomized Clinical Trial

Many people who use computers for long hours experience "cybersickness" (dizziness, nausea, blurred vision) because their eyes see movement on the screen but their body feels still. This study aims to see which type of eye and head exercises works best to fix this. We will compare Gaze Stabilization Exercises (head movements) against Oculomotor Exercises (eye movements). Forty-six computer users will perform these exercises for 4 weeks. We will measure their dizziness, vision, and quality of life before, during, and after the treatment.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This is a single-blinded, randomized clinical trial. Participants (n=46) will be recruited from The University of Faisalabad. Inclusion criteria include screen time >6 hours/day, computer usage for at least 10 years, and a Simulator Sickness Questionnaire (SSQ) score between 20 and 40.

Group A (Intervention): Gaze Stabilization Exercises. Week 1: View X1 exercises. Week 2: View X2 exercises. Week 3: Gaze shift exercises. Week 4: Imaginary Target exercises. (3 sessions/week, 1 minute per exercise, 3 times each).

Group B (Active Comparator): Oculomotor Exercises. Week 1: Range exercises. Week 2: Saccadic exercises. Week 3: Pursuit exercises. Week 4: Vergence exercises. (3 sessions/week, 1 minute per exercise, 3 times each).

Outcomes: The primary outcome is the change in Dynamic Visual Acuity (LogMAR scale) and Cybersickness (SSQ score). The secondary outcome is Quality of Life (SF-36 questionnaire). Measurements will be taken at baseline, Week 2, and Week 4. Data will be analyzed using SPSS version 20.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
46

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
    • Punjab Province
      • Faisalābad, Punjab Province, Pakistan, 3800
        • The University of Faisalabad

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Screen time > 6 hours per day
  • Computer usage history of at least 10 years
  • Complaints of vertigo, blurred vision, and nausea during computer usage
  • Positive Romberg's test
  • Abnormal VOR (4-6 lines lost on LogMAR scale)
  • SSQ score between 20 and 40

Exclusion Criteria:

  • Diagnosed vestibular disorders (e.g., BPPV, Meniere's)
  • History of falls in the past 6 months
  • Pregnancy
  • Any neurological or neurodegenerative disease
  • Use of walking aids
  • Severe visual impairments (worse than 6/12 on Snellen)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Gaze Stabilization Exercises
Participants in this arm will receive Gaze Stabilization Exercises (GSE) for 4 weeks, 3 sessions per week. The protocol includes View X1, View X2, Gaze Shift, and Imaginary Target exercises. Each exercise is performed for 1 minute, repeated 3 times per session. Exercises target the vestibulo-ocular reflex (VOR) by coordinating head and eye movements to reduce sensory conflict.
Behavioral: Gaze Stabilization Exercises
Week 1 - View X1: Patient sits upright. Target held at eye level 1 meter away. Patient turns head horizontally (left/right) or vertically (up/down) while keeping eyes fixed on target. Speed: slow (1Hz). Duration: 1 minute. Repetitions: 3 times per direction. Week 2 - View X2: Same as View X1 but head movement speed increased to 2Hz. Week 3 - Gaze Shift: Two targets placed 30 cm apart horizontally or vertically. Patient rotates head to face Target 1, then shifts gaze to Target 2 while continuing head rotation toward Target 2. Duration: 1 minute. Repetitions: 3 times. Week 4 - Imaginary Target: Patient fixates on a target (e.g., a sticker on wall). Closes eyes. Rotates head 30-45 degrees away from target. While eyes closed, patient imagines still looking at target. Opens eyes and checks if fixation is accurate. Duration: 1 minute. Repetitions: 3 times per direction. All exercises are performed under supervision for the first 3 sessions, then home-based with weekly follow-up calls.
Active Comparator: Oculomotor Exercises Group
Participants in this arm will receive Oculomotor Exercises for 4 weeks, 3 sessions per week. The protocol includes Range, Saccadic, Pursuit, and Vergence exercises. Each exercise is performed for 1 minute, repeated 3 times per session. Exercises target isolated eye movements without head motion to improve oculomotor control and reduce visual strain.
Behavioral: Oculomotor Exercises
Week 1 - Range Oculomotor Exercises: Eyes closed. Patient moves eyes slowly in horizontal (left-right), vertical (up-down), diagonal (top-left to bottom-right), and rotational (clockwise/counterclockwise) directions. Duration: 1 minute per direction. Repetitions: 3 times. Week 2 - Saccadic Exercises: Two stationary targets (e.g., two fingers) held 30 cm apart at eye level. Patient rapidly shifts gaze between targets without moving head. Duration: 1 minute. Repetitions: 3 times. Week 3 - Pursuit Exercises: A single target (e.g., pen) is moved slowly horizontally and vertically. Patient follows target smoothly with eyes only (head still). Speed: approx 20 degrees/second. Duration: 1 minute per direction. Repetitions: 3 times. Week 4 - Vergence Exercises: Target (e.g., pen) starts at 50 cm from patient's nose. Patient focuses on target as it is slowly moved toward nose to 5 cm (convergence), then back to 50 cm (divergence). Duration: 1 minute. Repetitions: 3 times under supervision.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in Vestibulo-Ocular Reflex (VOR) Function
Time Frame: Baseline (Week 0), Week 2, Week 4
Measured by Dynamic Visual Acuity (DVA) test using a LogMAR chart. Patient reads smallest line possible while head is stationary (static VA). Then patient rotates head horizontally at 2Hz while reading. Number of lines lost between static and dynamic conditions is recorded. Normal VOR: 1-2 lines lost. Abnormal: 4-6 lines lost. Higher lines lost = worse VOR function.
Baseline (Week 0), Week 2, Week 4
Change in Cybersickness Severity
Time Frame: Baseline (Week 0), Week 2, Week 4
Measured by the Simulator Sickness Questionnaire (SSQ). Contains 16 symptoms rated 0-3 (0=not at all, 3=severe). Total score range 0-48. Subscales: Nausea (symptoms 1,2,6,7,8,9,14,15), Oculomotor (3,4,5,10,11,12,13), and Disorientation (5,10,11,12,13,14,15). Higher score = worse cybersickness.
Baseline (Week 0), Week 2, Week 4

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in Quality of Life
Time Frame: Baseline (Week 0), Week 4
Measured by the Short Form-36 (SF-36) Health Survey. Contains 36 items measuring 8 domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, Mental Health. Scores transformed to 0-100 scale per domain. Higher score = better quality of life.
Baseline (Week 0), Week 4

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Faisalabad

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2026

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 10, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 22, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 23, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 23, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 1, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 1, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 23, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • TUF/EIRB/ 211 /26

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Vestibular Diseases

Clinical Trials on Gaze Stabilization Exercises

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings